

1 **Derivation, validation, and clinical relevance of a pediatric sepsis phenotype with**
2 **persistent hypoxemia and shock**

3
4 L. Nelson Sanchez-Pinto^{1,2*}; Tellen D. Bennett³; Emily Stroup⁴; Yuan Luo²; Mihir Atreya⁵; Juliane
5 Bubeck Wardenburg⁶; Grace Chong⁷; Alon Geva⁸; E. Vincent S. Faustino⁹; Reid W. Farris¹⁰;
6 Mark Hall¹¹; Colin Rogerson¹²; Sareen Shah¹³; Scott L. Weiss¹⁴; Robinder G. Khemani¹⁵

7
8 ¹Department of Pediatrics, Northwestern University Feinberg School of Medicine and Ann &
9 Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA; ²Department of Preventive
10 Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA;
11 ³Departments of Biomedical Informatics and Pediatrics, University of Colorado School of
12 Medicine, Aurora, CO, USA; ⁴Department of Pharmacology, Northwestern University Feinberg
13 School of Medicine, Chicago, IL, USA; ⁵Department of Pediatrics, University of Cincinnati
14 College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA;
15 ⁶Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA;
16 ⁷Department of Pediatrics, University of Chicago Pritzker School of Medicine, Chicago, IL, USA;
17 ⁸Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Children's Hospital,
18 Boston, MA, USA; Computational Health Informatics Program, Boston Children's Hospital,
19 Boston, MA, USA; Department of Anaesthesia, Harvard Medical School, Boston, MA, USA;
20 ⁹Department of Pediatrics, Yale School of Medicine, New Haven, CT, USA; ¹⁰Department of
21 Pediatrics, University of Washington and Seattle Children's Hospital, Seattle, WA, USA;
22 ¹¹Department of Pediatrics, The Ohio State University and Nationwide Children's Hospital,
23 Columbus, OH, USA; ¹²Department of Pediatrics, Indiana University School of Medicine, Riley
24 Hospital for Children, Indianapolis, IN, USA; ¹³Department of Pediatrics, Cohen Children's
25 Medical Center, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde
26 Park, NY, USA; ¹⁴Department of Anesthesiology and Critical Care, Children's Hospital of
27 Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA;
28 ¹⁵Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Los Angeles,
29 Los Angeles, CA, USA.

30
31 ***Corresponding Author:**

32 L. Nelson Sanchez-Pinto, MD, MBI
33 Division of Critical Care Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago
34 225 E. Chicago Ave, Box 73, Chicago, IL, 60611, USA
35 Phone: 312-227-4912; Email: lsanchezpinto@luriechildrens.org

36
37 **Word count:** 3,445

38
39 **Key words:** Critical Care; Pediatrics; Sepsis; Organ Dysfunction; Precision Medicine.

40
41
42
43

44

45 **ABSTRACT**

46 **Background**

47 Untangling the heterogeneity of sepsis in children and identifying clinically relevant phenotypes
48 could lead to the development of enrichment strategies and targeted therapies. In this study, our
49 aim was to analyze the organ dysfunction-based trajectories of children with sepsis-associated
50 multiple organ dysfunction syndrome (MODS) to identify and characterize reproducible and
51 clinically relevant sepsis phenotypes using a data-driven approach.

52 **Methods**

53 We collected data from patients admitted with suspected infections to 13 pediatric intensive care
54 units (PICUs) in the U.S. between 2012-2018. We used subgraph-augmented nonnegative
55 matrix factorization to identify candidate trajectory-driven phenotypes based on the type,
56 severity, and progression of organ dysfunction in the first 72 hours of PICU admission. We
57 analyzed the candidate phenotypes to determine reproducibility as well as prognostic,
58 therapeutic, and biological relevance.

59 **Results**

60 Overall, 38,732 children had suspected infection, of which 15,246 (39.4%) had sepsis-
61 associated MODS. Amongst patients with sepsis-associated MODS, 1,537 (10.1%) died in the
62 hospital. We identified an organ dysfunction trajectory-based phenotype (which we termed
63 *persistent hypoxemia and shock*) that was highly reproducible, had features of systemic
64 inflammation and coagulopathy, and was independently associated with higher mortality. In a
65 propensity score matched analysis, patients with the *persistent hypoxemia and shock*
66 phenotype appeared to have a higher likelihood to benefit from adjuvant therapy with
67 hydrocortisone and albumin than other patients. When compared to other high-risk clinical
68 syndromes, the *persistent hypoxemia and shock* phenotype only overlapped with 50 to 60% of
69 patients with septic shock, those with moderate-to-severe pediatric acute respiratory distress

70 syndrome, or those in the top tertile of organ dysfunction burden, suggesting that it represents a
71 distinct clinical phenotype of sepsis-associated MODS with a disproportionately high risk of
72 mortality.

73 **Conclusions**

74 We derived and validated the *persistent hypoxemia and shock* phenotype, a trajectory-based
75 organ dysfunction phenotype which is highly reproducible, clinically relevant, and associated
76 with heterogeneity of treatment effect to common adjuvant therapies. Further validation is
77 warranted. Future studies are needed to validate this phenotype, assess whether it can be
78 predicted earlier in the course, study possible biological mechanisms underlying it, and
79 investigate candidate therapeutic targets.

80

81 **Word count: 341**

82

83

84

85

86

87

88

89

90

91

92

93

94

95 **INTRODUCTION**

96 Sepsis is the most common cause of multiple organ dysfunction syndrome (MODS) in children,
97 which in turn frequently leads to death [1–4]. Although respiratory failure is the leading organ
98 dysfunction associated with pediatric sepsis and sepsis-related deaths [5,6], significant
99 heterogeneity exists in the clinical presentation and underlying pathobiology of children with
100 sepsis [7,8]. Untangling the clinical and biological heterogeneity in sepsis and acute respiratory
101 distress syndrome (ARDS) has been identified by the American Thoracic Society as a major
102 research priority in the path towards precision medicine in critical care [9].

103

104 A major challenge for untangling the heterogeneity of sepsis stems from the reality that the
105 pathobiology and clinical state of septic patients is dynamic [10,11]. Oftentimes, single time-
106 points (such as ICU admission or onset of disease) are used to investigate this heterogeneity,
107 but this approach fails to capture the critical importance of the evolving and dynamic nature of
108 sepsis [12,13]. Data from electronic health records (EHRs) provides an attractive opportunity to
109 perform data-driven analyses that incorporate the dimension of time by leveraging the granular,
110 longitudinal clinical data from thousands of patients [10,14]. Indeed, EHR data from adults with
111 sepsis and children with MODS has been used to uncover subgroups of patients with similar
112 clinical characteristics and trajectories (often called ‘phenotypes’ or ‘subphenotypes’) that have
113 been associated with clinically relevant findings, such as distinct cytokine profiles or
114 heterogeneity of treatment effect to interventions like balanced fluids or hydrocortisone
115 administration [3,15,16]. However, no prior study has used this approach to uncover trajectory-
116 based phenotypes in a large cohort of children with sepsis-associated MODS.

117

118 In this study, we aimed to derive and validate clinically relevant sepsis phenotypes using a data-
119 driven approach to analyze organ dysfunction trajectories in a large, multicenter cohort of

120 children with sepsis-associated MODS. We hypothesized that we would identify one or more
121 reproducible sepsis phenotypes based on the trajectories of organ dysfunctions in the acute
122 phase of critical illness and that patients with similar trajectories would have distinct risk factors,
123 biochemical characteristics, response to adjuvant therapies, and clinical outcomes.

124

125 **METHODS**

126 **Study design and patient population**

127 This was a retrospective, multicenter, observational cohort study of children 0 to 18 years old
128 admitted to one of 13 participating U.S. pediatric intensive care units (PICUs) in the six-year
129 period between January 1, 2012 and January 1, 2018. Data for patients who had a confirmed or
130 suspected infection (i.e., received systemic antimicrobials and microbiological testing in the +/-
131 24 hour time-window after the first admission to the PICU) were extracted from the EHRs of the
132 participating institutions using structured queries and underwent quality checks for conformity,
133 completeness, and plausibility using Kahn's framework [17]. Data with potential quality issues
134 were flagged and specific queries submitted back to the sites for clarification or re-extraction.
135 Validation of clinical values was assessed based on clinical standards and verification was
136 performed by comparing the distribution of values and count of variables across sites [17]. The
137 institutional review board (IRB) at Ann & Robert H. Lurie Children's Hospital of Chicago served
138 as the central IRB for this study. The reporting of this observational cohort study was performed
139 using the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
140 reporting guideline [18].

141

142 We measured the type, severity, and change in organ dysfunction using the six subscores of the
143 pediatric Sequential Organ Failure Assessment (pSOFA) score [1]. The pSOFA scores offers
144 several advantages for this type of analysis, including a normalized scale that has been
145 previously validated and shown to discriminate poor outcomes in critically ill children early in the

146 course better than other scores, as well as coverage of six key organ dysfunctions in sepsis:
147 neurologic, cardiovascular, respiratory, hepatic, renal, and coagulation [1,19]. The pSOFA
148 subscores were calculated for each 24-hour period between PICU admission and 72 hours,
149 which was used as a proxy for the acute phase of illness [14,20]. Individual pSOFA subscores
150 were carried forward until they were remeasured or the patient died; otherwise, if completely
151 missing they were assumed to be normal and the corresponding subscore was assigned a 0, as
152 previously performed [21,22]. We defined patients with MODS as those with a pSOFA subscore
153 of ≥ 2 in ≥ 2 organ systems [3]. For the unsupervised analysis, we only included patients with
154 sepsis-associated MODS, which were defined as those with confirmed or suspected infections
155 on admission and MODS within 72 hours. Patients with immunocompromised status were
156 defined as those with a malignancy and/or transplant comorbidity. The comorbidities of
157 malignancy, transplantation, and technology dependence were based on the classification
158 system developed by Feudtner et al. [3,23,24]. Severity of illness on admission was measured
159 using the Pediatric Risk of Mortality (PRISM) III score [25]. The vasoactive-inotropic score was
160 calculated to determine the degree of shock [26]. The primary outcome was in-hospital mortality
161 and the secondary outcome was persistent MODS on day 7 after PICU admission (including
162 patients who died in the first week) [3].

163

164 **Trajectory-based phenotyping**

165 Patients were split into three sets based on site, resulting in one derivation set (data from 7
166 sites) and two external validation sets (3 sites each), which is consistent with geographic-based
167 external validation, an approach recommended by established guidelines for clinical model
168 development and validation [27]. We first used subgraph-augmented nonnegative matrix
169 factorization (SANMF), an unsupervised trajectory modeling approach, to derive a set of organ
170 dysfunction trajectory-based groups as candidate phenotypes in the derivation set, as

171 previously performed by our group in children with MODS [3]. The SANMF analysis consisted of
172 two parts: (a) subgraph mining, in which the individual trajectories of each of the six pSOFA
173 subscores over the first 72 hours were analyzed to determine common patterns of severity and
174 change of the individual organ dysfunctions across patients; and (b) nonnegative matrix
175 factorization, in which patients were grouped into candidate phenotypes based on similarity in
176 the frequency of the subgraphs. The validation and clinical relevance of these candidate
177 phenotypes was then assessed across three dimensions based on an established framework
178 described by DeMerle et al. [28]. Briefly, the validation of the candidate phenotypes was
179 performed across three dimensions: (i) reproducibility of the candidate phenotypes in the first
180 validation set using the SANMF mixture coefficient matrix to assess external validity; (ii)
181 reproducibility of the candidate phenotypes using different unsupervised trajectory modeling
182 methods in the derivation and first validation set (using repeated measures latent class analysis
183 [RM-LCA] and group-based trajectory modeling [GBTM]) to assess statistical approach validity;
184 and (iii) reproducibility of the candidate phenotypes in the second external validation set using a
185 Random Forest classifier to assess whether the SANMF-based phenotypes groups can be
186 accurately predicted in new datasets. The clinical relevance of the candidate phenotypes was
187 also assessed across three dimensions: (i) prognostic relevance based on the independent
188 association with outcomes; (ii) therapeutic relevance based on the association with response to
189 two adjuvant therapies (intravenous hydrocortisone and albumin); and (iii) pathobiological
190 relevance based on association with biochemical and clinical features linked to plausible
191 disease mechanisms and other clinical syndromes. The adjuvant therapies studied
192 (hydrocortisone and albumin) were chosen *a priori* because they are commonly used in sepsis
193 and have plausible mechanisms of action, but have conflicting evidence regarding their efficacy
194 [5].
195
196 Additional details on the Methods are included in the Online Data Supplement.

197

198 **Statistical Analysis**

199 Categorical variables were compared using the chi-squared test and continuous variables using
200 the Kruskal-Wallis test. Agreement between models was assessed using Fleiss' Kappa. Mixed
201 effects logistic regression was used to adjust for confounders when comparing the association
202 of candidate phenotypes with outcomes. The random effect was based on the study site and the
203 fixed effects included age, immunocompromised status, and severity of organ dysfunction in the
204 first 72 hours using the mean pSOFA score. Propensity score matching was used to account for
205 selection bias in the response to treatment analysis. The propensity score to receive either of
206 the studied treatments in the first 24 hours of admission was based on the risk factors that were
207 significantly associated with a higher likelihood of receiving the treatment. To limit the influence
208 of survival bias on whether a patient received or did not receive a treatment, only patients alive
209 for at least 24 hours were included in the propensity matched analysis. A sensitivity analysis of
210 the therapeutic relevance of phenotype membership in all patients was performed using inverse
211 probability treatment weighting (IPTW). Survival analysis to 28 days was performed using
212 Kaplan-Meier curves and Cox regression analysis. Statistical significance was set at $p < 0.05$.
213 Data were analyzed using R version 4.0 (R Project for Statistical Computing, Vienna, Austria)
214 and STATA, version 16 (Stata Corp LLC, College Station, TX).

215

216 **RESULTS**

217 **Study population**

218 There were 38,732 children with suspected or confirmed infection on admission to the PICU. Of
219 those, 15,246 (39.4%) had sepsis-associated MODS, of whom 1,537 (10.1%) died in the
220 hospital. Sites contributed a median of 1,167 patients with sepsis-associated MODS
221 (interquartile range [IQR] 837, 1596). The median unadjusted site-specific in-hospital mortality
222 was 9.9% (IQR 8.2%, 13.1%), which was significantly different across sites ($p < 0.001$). Table E1

223 presents the clinical characteristics and outcomes of patients with and without sepsis-
224 associated MODS in the cohort. Children with sepsis-associated MODS were randomly split by
225 site into a derivation set (7 sites with 7,503 patients), a first external validation set (3 sites with
226 3,484 patients), and a second external validation set (3 sites with 4,259 patients).

227

228 **Derivation of trajectory-based candidate phenotypes using SANMF**

229 Subgraph mining uncovered 776 frequent subgraphs representing individual organ dysfunction
230 trajectories in patients with sepsis-associated MODS in the derivation set. 7,448 patients (99.3%
231 of the derivation set) had at least one frequent subgraph and were included in the SANMF
232 analysis. In the SANMF analysis, patients were separated into four trajectory-based groups
233 based on the cophenetic correlation and the group size. Groups 1, 3, and 4 had an overall
234 trajectory towards recovery of their organ dysfunctions in the first 72 hours (Figure E1) and
235 associated in-hospital mortalities in the 4.3%-6.3% range. Group 2 represented the only high-
236 risk group with an in-hospital mortality of 20.9% and was characterized by a trajectory of
237 persistent organ dysfunction in the first 72 hours, predominantly respiratory, neurologic, and
238 cardiovascular dysfunctions (Table E2).

239

240 **Reproducibility of the candidate phenotypes**

241 Reproducibility of the SANMF groups in an external validation set was performed by applying
242 the SANMF mixture coefficient matrix from the derivation set to the frequent subgraph counts of
243 the first validation set. This demonstrated very reproducible distributions (i.e. proportion of
244 patients in each group) and associated clinical outcome across the derivation and first validation
245 sets (Table E2).

246

247 We then compared the overlap of the four SANMF-derived groups with the trajectory groups
248 derived using RM-LCA and GBTM. Only SANMF Group 2 had significant overlap with the

249 groups derived by RM-LCA and GBTM (Table E3). Specifically, RM-LCA Class 3 had a 78%
250 overlap with SANMF Group 2 and GBTM Group 4 had 79% overlap with SANMF Group 2. The
251 agreement between the models for these three groups was moderate (Fleiss' Kappa = 0.5,
252 $p < 0.001$). All other overlaps ranged from 1 to 48% and had poor agreement.

253

254 **Clinical characterization and external reproducibility using a classifier**

255 SANMF Group 2 was selected for further characterization as a sepsis phenotype because of its
256 association with poor outcomes and its reproducibility across an external validation set and after
257 using three different unsupervised trajectory modeling approaches. Based on the type, severity,
258 and trajectory of the organ dysfunctions associated with the phenotype, we labeled it *persistent*
259 *hypoxemia and shock* and grouped the rest of the patients under the label *other sepsis-*
260 *associated MODS* (Figure 1).

261

262 We then trained a Random Forest classifier on the derivation set using the 18 daily pSOFA
263 subscores as features (6 subscores per day for 3 days) and the *persistent hypoxemia and*
264 *shock* phenotype as the outcome. The classifier had excellent performance at predicting the
265 *persistent hypoxemia and shock* phenotype in the first validation set (area under the curve =
266 0.97, 95% confidence interval [CI] 0.96-0.97). The variable importance for the Random Forest is
267 presented in Figure E2. When the model was applied to the second external validation set,
268 patients classified as *persistent hypoxemia and shock* had a similar distribution, severity of
269 illness, and outcomes when compared to patients with the phenotype in the derivation set and
270 first validation set, with some differences in the rate of comorbidities and organ support use
271 reflective of the baseline populations in the different sites (Table E4). Table 1 presents the
272 clinical characteristics and outcomes of patients with *persistent hypoxemia and shock*
273 phenotype compared to patients with other sepsis-associated MODS in the entire cohort.

274

275 **Prognostic relevance**

276 In the mixed effects model, after adjusting for age, immunocompromised state, and mean
277 pSOFA score in the first 72 hours, the *persistent hypoxemia and shock* phenotype was
278 associated with a four-fold higher odds of in-patient mortality and a two-fold higher odds of
279 persistent MODS at 7 days (Table 2). Figure E3 presents the Kaplan-Meier survival curve of the
280 *persistent hypoxemia and shock* phenotype compared to patients with other sepsis-associated
281 MODS.

282

283 **Therapeutic relevance**

284 Overall, 14,983 patients survived for >24 hours and were included in the propensity matched
285 analysis. The risk factors associated with higher likelihood of receiving hydrocortisone or
286 albumin were: age, immunocompromised status, admission source, PRISM III score,
287 vasoactive-inotropic score (VIS), and study site (Tables E5-E7). We used those factors to
288 perform the propensity score matching (PSM) analysis. Using PSM, we matched 1,648 patients
289 who received hydrocortisone (95%), and 1,162 patients who received albumin (100%) to
290 untreated controls with similar propensity scores. Adequate covariate balance was achieved in
291 both the hydrocortisone (Figure E4) and albumin (Figure E6) analyses. We found a significant
292 interaction between the *persistent hypoxemia and shock* phenotype and both hydrocortisone
293 and albumin use: treated patients with the phenotype had lower mortality and less MODS at 7
294 days compared to patients with other sepsis-associated MODS (Table 3). The Kaplan-Meier
295 curves of treated and matched untreated patients with or without the *persistent hypoxemia and*
296 *shock* phenotype are presented in Figures E5 and E7.

297

298 In the sensitivity analysis using IPTW in the entire cohort with the same risk factors as in the
299 PSM analysis, the interaction between the *persistent hypoxemia and shock* phenotype and
300 hydrocortisone or albumin use were associated with lower in-hospital mortality ($p < 0.001$).

301

302 **Pathobiological relevance**

303 Patients with the *persistent hypoxemia and shock* had more systemic inflammation,
304 coagulopathy, and signs of hypoperfusion than patients with other sepsis-associated MODS
305 (Table 4). Among the 689 patients (4.5%) who had a ferritin level obtained, the majority of
306 patients with *persistent hypoxemia and shock* had hyperferritinemia, with more than half
307 reaching levels >1000 ng/mL (Table 4).

308

309 When compared to other high-risk clinical syndromes in the first 72 hours of admission, the
310 *persistent hypoxemia and shock* phenotype overlapped with 55% of patients meeting septic
311 shock criteria, 54% of patients meeting moderate-to-severe pediatric ARDS criteria, and 62% of
312 patient in the top tertile of organ dysfunction burden based on the mean pSOFA score (Table
313 E8).

314

315 Finally, the *persistent hypoxemia and shock* phenotype was more common in younger patients,
316 especially <1 year old, where the prevalence was 36-45% compared to 28-32% in the older age
317 groups (Table E9).

318

319 **DISCUSSION**

320 In this study, we derived and validated the *persistent hypoxemia and shock* phenotype in
321 children with sepsis-associated MODS. This trajectory-based sepsis phenotype had features of
322 systemic inflammation and coagulopathy, was present in approximately one third of children
323 with sepsis-associated MODS, and was independently associated with mortality. Classification
324 of this phenotype was highly reproducible in two external validation sets and using various
325 statistical methods for trajectory modeling. Additionally, in a propensity score analysis, patients
326 with *persistent hypoxemia and shock* appeared to have a higher likelihood to benefit from

327 adjuvant therapy with hydrocortisone and albumin when compared to other patients with sepsis-
328 associated MODS. Finally, the *persistent hypoxemia and shock* phenotype overlapped with only
329 about half of the patients with septic shock, half of those with moderate-to-severe pediatric
330 ARDS, and less than two thirds of those with the highest organ dysfunction burden based on the
331 mean pSOFA score in the first 72 hours. These latter findings highlight the fact that this
332 phenotype does not simply describe the sickest patients or those recognizable as septic shock
333 or ARDS at the bedside, instead it suggests that the *persistent hypoxemia and shock* phenotype
334 represents a distinct clinical phenotype of sepsis-associated MODS with a disproportionately
335 high risk of mortality, accounting for almost 70% of all deaths in patients in this cohort.

336
337 Prior studies have identified phenotypes with characteristics similar to the *persistent hypoxemia*
338 *and shock* phenotype. Knox et al. described the *shock with hypoxemia and altered mental*
339 *status* phenotype and Seymour et al. described the γ phenotype in adult sepsis patients, which
340 share similar features, including hypoxemia, vasoactive dependence, inflammation, and high
341 mortality [12,13]. In follow up studies, the γ phenotype has been found to be particularly
342 predominant in patients with viral and bacterial pneumonia, which are common etiologies of
343 sepsis and respiratory failure in children [29]. Calfee et al. and Dahmer et al. have also
344 described a *hyperinflammatory* phenotype of ARDS in adults and children, respectively, which
345 share many common features with the *persistent hypoxia and shock* phenotype [30,31]. Similar
346 to our findings, the *hyperinflammatory* ARDS phenotype is commonly associated with more
347 sepsis, inflammation, hypotension, and coagulopathy than other patients with ARDS [30–32].
348 Importantly, Calfee and colleagues have shown that the *hyperinflammatory* ARDS phenotype is
349 associated with heterogeneity of treatment effect to various common interventions, including
350 ventilator strategies and fluid management [30,33,34]. Additionally, our group previously
351 described a high-risk phenotype with severe hypoxemia and shock in children with MODS (both
352 with and without sepsis) in a two-center study [3]. On a related concept, Villar et al. performed

353 an enrichment strategy in their ARDS randomized controlled trial by only enrolling adult patients
354 who had persistent hypoxemia 24 hours after initial ARDS diagnosis and found that patients
355 who met that persistent hypoxemia criteria and received dexamethasone had a significantly
356 lower mortality than controls [35]. Finally, Carcillo et al. have described the hyperferritinemic
357 response in sepsis as a distinct, high-risk phenotype characterized by macrophage activation
358 that is potentially susceptible to anti-cytokine therapy [8,36,37]. Importantly, macrophage
359 activation appears to be a key mechanism in sepsis-related lung injury [38–41].

360
361 Our findings have important implications. While risk stratifying critically ill children with infections
362 and sepsis early in the course is important for diagnostic purposes, the clinical reality is that
363 most children with sepsis will suffer their worst degree of MODS on the day of admission. Most
364 of them, even those with significant organ dysfunction, will tend to follow a trajectory of recovery
365 after admission, as observed in our cohort and in previous studies [4,42]. Thus, understanding
366 which children with sepsis will have a trajectory of persistent or worsening organ dysfunction,
367 what patterns of dysfunction are expected in those children, and why they display those patterns
368 from a pathobiological standpoint, become questions of paramount importance. In our study we
369 have identified a high-risk, highly reproducible trajectory-based phenotype of pediatric sepsis
370 with both prognostic and therapeutic relevance. However, the *persistent hypoxemia and shock*
371 phenotype requires longitudinal information for patient classification. In order for this type of
372 classification to be clinically useful it would need to be predicted earlier in the clinical course.
373 Prediction of phenotype membership is the next, important step in this line of research and
374 could be performed through a combination of machine learning approaches using EHR data
375 [43], rapid-turnaround biomarkers (including ferritin and novel cytokine profiles) [44], and other
376 physiological markers like low heart rate variability, which is associated with pro-inflammatory
377 states and progressive organ dysfunction [45,46].

378

379 Our study has several strengths and limitations. We performed our analysis using a large,
380 granular, multicenter cohort with wide geographic and racial-ethnic representation of children in
381 the United States. Furthermore, we derived and validated the *persistent hypoxemia and shock*
382 phenotypes using data that was partitioned by study sites, which allowed us to test the external
383 validity and generalizability of the phenotype. However, our dataset was observational in nature,
384 and thus susceptible to selection bias and the uncertainty introduced by missing data. While we
385 used standard approaches to ensure data quality, deal with missing data, and adjust for
386 confounders, further validation of our findings is needed. Finally, our therapeutic relevance
387 analysis using propensity scoring is susceptible to residual confounding and must be interpreted
388 with caution.

389

390 In conclusion, we derived and validated the *persistent hypoxemia and shock* phenotype, a
391 trajectory-based organ dysfunction phenotype which was present in a third of children with
392 sepsis-associated MODS and associated with more than two thirds of deaths. This phenotype is
393 associated with systemic inflammation and coagulopathy, is independently associated with
394 higher mortality, and is associated with heterogeneity of treatment effect to common adjuvant
395 therapies. Future studies are needed to ascertain the reproducibility of this phenotype, assess
396 whether it can be predicted earlier in the course, further study the possible biological
397 mechanisms underlying it, and investigate candidate therapeutic targets.

398

399

400

401

402

403

404

405 **ACKNOWLEDGEMENTS**

406 The authors would like to acknowledge and thank the late Dr. Hector Wong (1963-2022), who
407 was an early collaborator and supporter of this work.

408

409 **AUTHOR CONTRIBUTIONS**

410 *Concept, design and drafting of manuscript: LNS; Analysis: LNS, ES; Acquisition and/or*
411 *interpretation of the data, revising manuscript critically for important intellectual content and final*
412 *approval of the version to be published: All authors*

413

414 **FUNDING**

415 This study was supported by the NIH (R21HD096402, Sanchez-Pinto).

416

417 **AVAILABILITY OF DATA**

418 The datasets generated and analyzed during the current study are not publicly available due
419 institutional review board restrictions given that it contains personal health information, but are
420 available from the corresponding author on reasonable request.

421

422 **DECLARATIONS**

- 423
- 424 • The institutional review board at Ann & Robert H. Lurie Children's Hospital of Chicago
425 served as the central review board for this study and approved it with a waiver of
426 consent.
 - 427 • The authors declare no financial conflicts of interest related to this study.
- 428

427

428

429

430 REFERENCES

- 431 1. Matics TJ, Sanchez-Pinto LN. Adaptation and Validation of a Pediatric Sequential Organ
432 Failure Assessment Score and Evaluation of the Sepsis-3 Definitions in Critically Ill Children.
433 *JAMA Pediatr.* 2017;171:e172352.
- 434 2. Weiss SL, Balamuth F, Hensley J, Fitzgerald JC, Bush J, Nadkarni VM, et al. The
435 Epidemiology of Hospital Death Following Pediatric Severe Sepsis: When, Why, and How
436 Children With Sepsis Die. *Pediatr Crit Care Med.* 2017;18:823–30.
- 437 3. Sanchez-Pinto LN, Stroup EK, Pendergrast T, Pinto N, Luo Y. Derivation and Validation of
438 Novel Phenotypes of Multiple Organ Dysfunction Syndrome in Critically Ill Children. *JAMA Netw*
439 *Open.* 2020;3:e209271.
- 440 4. Lin JC, Spinella PC, Fitzgerald JC, Tucci M, Bush JL, Nadkarni VM, et al. New or Progressive
441 Multiple Organ Dysfunction Syndrome in Pediatric Severe Sepsis [Internet]. *Pediatric Critical*
442 *Care Medicine.* 2017. p. 8–16. Available from: <http://dx.doi.org/10.1097/pcc.0000000000000978>
- 443 5. Weiss SL, Fitzgerald JC, Pappachan J, Wheeler D, Jaramillo-Bustamante JC, Salloo A, et al.
444 Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies
445 study. *Am J Respir Crit Care Med.* 2015;191:1147–57.
- 446 6. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global,
447 regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden
448 of Disease Study. *Lancet.* 2020;395:200–11.
- 449 7. Wong HR, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, Bigham MT, et al. Developing a
450 clinically feasible personalized medicine approach to pediatric septic shock. *Am J Respir Crit*
451 *Care Med.* 2015;191:309–15.
- 452 8. Carcillo JA, Berg RA, Wessel D, Pollack M, Meert K, Hall M, et al. A Multicenter Network
453 Assessment of Three Inflammation Phenotypes in Pediatric Sepsis-Induced Multiple Organ
454 Failure. *Pediatr Crit Care Med.* 2019;20:1137–46.
- 455 9. Shah FA, Meyer NJ, Angus DC, Awdish R, Azoulay É, Calfee CS, et al. A Research Agenda
456 for Precision Medicine in Sepsis and Acute Respiratory Distress Syndrome: An Official
457 American Thoracic Society Research Statement. *Am J Respir Crit Care Med.* 2021;204:891–
458 901.
- 459 10. Xu Z, Mao C, Su C, Zhang H, Siempos I, Torres LK, et al. Sepsis subphenotyping based on
460 organ dysfunction trajectory. *Crit Care.* 2022;26:197.
- 461 11. Wong HR, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, Bigham MT, et al. Endotype
462 Transitions During the Acute Phase of Pediatric Septic Shock Reflect Changing Risk and
463 Treatment Response. *Crit Care Med.* 2018;46:e242–9.
- 464 12. Seymour CW, Kennedy JN, Wang S, Chang C-CH, Elliott CF, Xu Z, et al. Derivation,
465 Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis. *JAMA.*
466 2019;321:2003–17.
- 467 13. Knox DB, Lanspa MJ, Kuttler KG, Brewer SC, Brown SM. Phenotypic clusters within sepsis-

- 468 associated multiple organ dysfunction syndrome [Internet]. *Intensive Care Medicine*. 2015. p.
469 814–22. Available from: <http://dx.doi.org/10.1007/s00134-015-3764-7>
- 470 14. Bhavani SV, Carey KA, Gilbert ER, Afshar M, Verhoef PA, Churpek MM. Identifying Novel
471 Sepsis Subphenotypes Using Temperature Trajectories. *Am J Respir Crit Care Med*.
472 2019;200:327–35.
- 473 15. Bhavani SV, Semler M, Qian ET, Verhoef PA, Robichaux C, Churpek MM, et al.
474 Development and validation of novel sepsis subphenotypes using trajectories of vital signs.
475 *Intensive Care Med* [Internet]. 2022; Available from: [http://dx.doi.org/10.1007/s00134-022-](http://dx.doi.org/10.1007/s00134-022-06890-z)
476 06890-z
- 477 16. Bhavani SV, Wolfe KS, Hrusch CL, Greenberg JA, Krishack PA, Lin J, et al. Temperature
478 Trajectory Subphenotypes Correlate With Immune Responses in Patients With Sepsis. *Crit*
479 *Care Med*. 2020;48:1645–53.
- 480 17. Kahn MG, Callahan TJ, Barnard J, Bauck AE, Brown J, Davidson BN, et al. A Harmonized
481 Data Quality Assessment Terminology and Framework for the Secondary Use of Electronic
482 Health Record Data. *EGEMS (Wash DC)*. 2016;4:1244.
- 483 18. Elm E von, von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, et al. The
484 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement:
485 Guidelines for Reporting Observational Studies [Internet]. *PLoS Medicine*. 2007. p. e296.
486 Available from: <http://dx.doi.org/10.1371/journal.pmed.0040296>
- 487 19. Sanchez-Pinto LN, Parker WF, Mayampurath A, Derrington S, Michelson KN. Evaluation of
488 Organ Dysfunction Scores for Allocation of Scarce Resources in Critically Ill Children and Adults
489 During a Healthcare Crisis. *Crit Care Med*. 2021;49:271–81.
- 490 20. Moreno R, Vincent JL, Matos R, Mendonça A, Cantraine F, Thijs L, et al. The use of
491 maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a
492 prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM.
493 *Intensive Care Med*. 1999;25:686–96.
- 494 21. Raith EP, Udy AA, Bailey M, McGloughlin S, Maclsaac C, Bellomo R, et al. Prognostic
495 Accuracy of the SOFA Score, SIRS Criteria, and qSOFA Score for In-Hospital Mortality Among
496 Adults With Suspected Infection Admitted to the Intensive Care Unit [Internet]. *JAMA*. 2017. p.
497 290. Available from: <http://dx.doi.org/10.1001/jama.2016.20328>
- 498 22. Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, et al. Assessment
499 of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and
500 Septic Shock (Sepsis-3). *JAMA*. 2016;315:762–74.
- 501 23. Feudtner C, Feinstein JA, Zhong W, Hall M, Dai D. Pediatric complex chronic conditions
502 classification system version 2: updated for ICD-10 and complex medical technology
503 dependence and transplantation [Internet]. *BMC Pediatrics*. 2014. Available from:
504 <http://dx.doi.org/10.1186/1471-2431-14-199>
- 505 24. Feinstein JA, Russell S, DeWitt PE, Feudtner C, Dai D, Bennett TD. R Package for Pediatric
506 Complex Chronic Condition Classification. *JAMA Pediatr*. 2018;172:596–8.
- 507 25. Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated Pediatric Risk of Mortality

- 508 score. *Crit Care Med.* 1996;24:743–52.
- 509 26. Gaies MG, Gurney JG, Yen AH, Napoli ML, Gajarski RJ, Ohye RG, et al. Vasoactive-
510 inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass.
511 *Pediatr Crit Care Med.* 2010;11:234–8.
- 512 27. Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, et al.
513 Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis
514 (TRIPOD): explanation and elaboration. *Ann Intern Med.* 2015;162:W1–73.
- 515 28. DeMerle KM, Angus DC, Baillie JK, Brant E, Calfee CS, Carcillo J, et al. Sepsis Subclasses:
516 A Framework for Development and Interpretation. *Crit Care Med.* 2021;49:748–59.
- 517 29. Bruse N, Kooistra EJ, Jansen A, van Amstel RBE, de Keizer NF, Kennedy JN, et al. Clinical
518 sepsis phenotypes in critically ill COVID-19 patients. *Crit Care.* 2022;26:244.
- 519 30. Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA, et al.
520 Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two
521 randomised controlled trials. *Lancet Respir Med.* 2014;2:611–20.
- 522 31. Dahmer MK, Yang G, Zhang M, Quasney MW, Sapru A, Weeks HM, et al. Identification of
523 phenotypes in paediatric patients with acute respiratory distress syndrome: a latent class
524 analysis. *Lancet Respir Med.* 2022;10:289–97.
- 525 32. Sinha P, Delucchi KL, Chen Y, Zhuo H, Abbott J, Wang C, et al. Latent class analysis-
526 derived subphenotypes are generalisable to observational cohorts of acute respiratory distress
527 syndrome: a prospective study. *Thorax.* 2022;77:13–21.
- 528 33. Alipanah N, Calfee CS. Phenotyping in acute respiratory distress syndrome: state of the art
529 and clinical implications. *Curr Opin Crit Care.* 2022;28:1–8.
- 530 34. Famous KR, Delucchi K, Ware LB, Kangelaris KN, Liu KD, Thompson BT, et al. Acute
531 Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid
532 Management Strategy. *Am J Respir Crit Care Med.* 2017;195:331–8.
- 533 35. Villar J, Ferrando C, Martínez D, Ambrós A, Muñoz T, Soler JA, et al. Dexamethasone
534 treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial.
535 *Lancet Respir Med.* 2020;8:267–76.
- 536 36. Carcillo JA, Kernan KK, Horvat CM, Simon DW, Aneja RK. Why and How Is
537 Hyperferritinemic Sepsis Different From Sepsis Without Hyperferritinemia? *Pediatr. Crit. Care*
538 *Med.* 2020. p. 509–12.
- 539 37. Carcillo JA, Halstead ES, Hall MW, Nguyen TC, Reeder R, Aneja R, et al. Three
540 Hypothetical Inflammation Pathobiology Phenotypes and Pediatric Sepsis-Induced Multiple
541 Organ Failure Outcome. *Pediatr Crit Care Med.* 2017;18:513–23.
- 542 38. Herold S, Steinmueller M, von Wulffen W, Cakarova L, Pinto R, Pleschka S, et al. Lung
543 epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-
544 related apoptosis-inducing ligand [Internet]. *Journal of Experimental Medicine.* 2008. p. 3065–
545 77. Available from: <http://dx.doi.org/10.1084/jem.20080201>
- 546 39. Lin KL, Suzuki Y, Nakano H, Ramsburg E, Gunn MD. CCR2+ monocyte-derived dendritic

- 547 cells and exudate macrophages produce influenza-induced pulmonary immune pathology and
548 mortality. *J Immunol*. 2008;180:2562–72.
- 549 40. Coates BM, Staricha KL, Koch CM, Cheng Y, Shumaker DK, Scott Budinger GR, et al.
550 Inflammatory Monocytes Drive Influenza A Virus–Mediated Lung Injury in Juvenile Mice
551 [Internet]. *The Journal of Immunology*. 2018. p. 2391–404. Available from:
552 <http://dx.doi.org/10.4049/jimmunol.1701543>
- 553 41. Kumar V. Pulmonary Innate Immune Response Determines the Outcome of Inflammation
554 During Pneumonia and Sepsis-Associated Acute Lung Injury [Internet]. *Frontiers in*
555 *Immunology*. 2020. Available from: <http://dx.doi.org/10.3389/fimmu.2020.01722>
- 556 42. Menon K, Schlapbach LJ, Akech S, Argent A, Biban P, Carrol ED, et al. Criteria for Pediatric
557 Sepsis-A Systematic Review and Meta-Analysis by the Pediatric Sepsis Definition Taskforce.
558 *Crit Care Med*. 2022;50:21–36.
- 559 43. Maddali MV, Churpek M, Pham T, Rezoagli E, Zhuo H, Zhao W, et al. Validation and utility
560 of ARDS subphenotypes identified by machine-learning models using clinical data: an
561 observational, multicohort, retrospective analysis. *Lancet Respir Med*. 2022;10:367–77.
- 562 44. Carlton EF, McHugh WM, McDonough K, Sturza J, Desch K, Cornell TT. Markers of
563 Endothelial Dysfunction and Cytokines in High-Risk Pediatric Patients with Severe Sepsis. *Am J*
564 *Respir Crit Care Med*. 2020;201:380–4.
- 565 45. Badke CM, Carroll MS, Weese-Mayer DE, Sanchez-Pinto LN. Association Between Heart
566 Rate Variability and Inflammatory Biomarkers in Critically Ill Children. *Pediatr Crit Care Med*.
567 2022;23:e289–94.
- 568 46. Badke CM, Marsillio LE, Carroll MS, Weese-Mayer DE, Sanchez-Pinto LN. Development of
569 a Heart Rate Variability Risk Score to Predict Organ Dysfunction and Death in Critically Ill
570 Children. *Pediatr Crit Care Med*. 2021;22:e437–47.
- 571
- 572
- 573
- 574
- 575
- 576
- 577
- 578
- 579

580 **FIGURE LEGEND**

581 **Figure 1.** Type, severity, and trajectory of the organ dysfunctions associated with the *persistent*
582 *hypoxemia and shock* phenotype.

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602 **TABLES**

603 **Table 1.** Clinical characteristics of children with the *persistent hypoxemia and shock* phenotype
 604 and those with *other sepsis-associated MODS*.

Variables	Persistent Hypoxemia and Shock (n=4,836)	Other Sepsis-associated MODS (n=10,410)	
Age, years (IQR)	4.3 (1, 11.7)	5.2 (1.4, 11.8)	<0.001
Male, No. (%)	2,637 (54.5)	5,742 (55.2)	0.478
Race/Ethnicity, No. (%)			
White, Non-Hispanic	2,279 (47.1)	5,127 (49.3)	0.009
Black	870 (18.0)	1,754 (16.8)	
Hispanic	875 (18.1)	1,966 (18.9)	
Asian	213 (4.4)	424 (4.1)	
Other	599 (12.4)	1,139 (10.9)	
Comorbidities, No. (%)			
Immunocompromised	953 (19.7)	1,955 (18.8)	0.183
Technology Dependent	2,166 (44.8)	4,733 (45.5)	0.445

Admission Source, No. (%)			
Emergency Department	2,000 (41.4)	4,789 (46.0)	<0.001
Hospital Floor	1,091 (22.6)	2,305 (22.1)	
Direct/Transport	1,307 (27.0)	2,118 (20.3)	
Operating Room	438 (9.1)	1,198 (11.5)	
Season, No. (%)			
Spring	1,254 (25.9)	2,686 (25.8)	0.066
Summer	1,028 (21.3)	2,262 (21.7)	
Fall	1,063 (22.0)	2,442 (23.5)	
Winter	1,491 (30.8)	3,020 (29.0)	
Year, No. (%)			
2012-2013	1,466 (30.3)	3,117 (29.9)	0.563
2014-2015	1,601 (33.1)	3,538 (34.0)	
2016-2017	1,769 (36.6)	3,755 (36.1)	
PRISM III score (IQR)	15 (10, 23)	9 (5, 14)	<0.001
Organ support, No (%)			

Mechanical ventilation	3,787 (78.3)	5,940 (57.1)	<0.001
Vasoactive infusion	3,348 (69.2)	2,844 (27.3)	<0.001
CRRT	390 (8.1)	208 (2.0)	<0.001
ECMO	337 (7.0)	70 (0.7)	<0.001
Outcomes			
Length of stay, days (IQR)	15 [7, 29]	9 (5, 18)	<0.001
Persistent MODS on day 7, No. (%)	2,446 (50.6)	1,722 (16.5)	<0.001
In-hospital mortality, No. (%)	1,045 (21.6)	492 (4.7)	<0.001

605 Abbreviations: *IQR*, interquartile range; *PRISM III*, Pediatric risk of mortality version 3; *CRRT*,

606 continuous renal replacement therapy; *ECMO*, extracorporeal membrane oxygenation.

607

608

609

610

611

612

613

614

615

616

617 **Table 2.** Prognostic relevance associated with the persistent hypoxemia and shock phenotype

618 based on the generalized linear mixed effects models.

Fixed effects	Adjusted OR* (95% CI) for In-Hospital Mortality	Adjusted OR* (95% CI) for Persistent MODS on day 7
Persistent hypoxemia and shock phenotype	4 (2.9, 5.5)	2 (1.6, 2.6)
Mean pSOFA by 72 hours	1.4 (1.4, 1.5)	1.8 (1.7, 1.9)
Age, years	1 (0.9, 1)	1 (1, 1)
Immunocompromised	1.7 (1.2, 2.5)	1 (0.7, 1.4)

619 *The random effect was the study site

620 Abbreviations: *OR*, odds ratio; *CI*, confidence interval; *MODS*, multiple organ dysfunction

621 syndrome; *pSOFA*, pediatric sequential organ failure assessment.

622

623

624

625

626

627

628

629 **Table 3.** Therapeutic relevance associated with the *persistent hypoxemia and shock* phenotype
 630 based on the propensity score matched analysis.

Treatment and outcomes	Matched persistent hypoxemia and shock phenotype		Matched other sepsis-associated MODS		P-value (interaction)
	Yes (n=772)	No (n=770)	Yes (n=876)	No (n=878)	
Received hydrocortisone*					
Persistent MODS on day 7, No. (%)	415 (53.8)	457 (59.4)	194 (22.1)	176 (20)	0.023
In-hospital mortality after 24h, No. (%)	190 (24.6)	239 (31)	78 (9)	71 (8)	0.039
Received albumin**					
Persistent MODS on day 7, No. (%)	337 (57.8)	305 (61)	163 (28.2)	136 (20.5)	0.003
In-hospital mortality after 24h, No. (%)	143 (24.5)	168 (33.6)	53 (9)	47 (7)	0.004

631 *≥ 1mg/kg of intravenous hydrocortisone in the first 24 hours.

632 **≥ 0.5 g/kg of albumin infusion in the first 24 hours.

633 Abbreviation: *MODS*, multiple organ dysfunction syndrome.

634 **Table 4.** Biochemical characteristics of the *persistent hypoxemia and shock phenotype*
 635 compared to other sepsis-associated MODS.

Variables	Patients with values	Persistent Hypoxemia and Shock (n=4,836)	Other Sepsis-associated MODS (n=10,410)	p-value
Laboratory results, median (IQR)*				
Min. Abs. lymphocytes, K/uL	11,877	0.99 (0.43, 1.81)	1.17 (0.54, 2.14)	<0.001
Min. Hemoglobin, g/dL	13,292	8.3 (7.1, 9.7)	9.0 (7.5, 10.5)	<0.001
Max. WBC, K/uL	12,812	12.9 (7.8, 20.2)	11.20 (6.9, 17)	<0.001
Max. Bands, %	6,205	13 (5, 25)	9 (3, 19)	<0.001
Max. CRP, mg/dL	3,886	9.5 (3.3, 22.9)	6.7 (2.5, 18.3)	<0.001
Max. Ferritin, ng/mL	689	1102 (315, 9407)	435 (154, 2774)	<0.001
Min. Platelets, K/uL	12,768	105 (42, 199)	149 (63, 238)	<0.001
Max. INR	7,713	1.6 (1.3, 2.1)	1.3 (1.2, 1.7)	<0.001
Max. PTT, sec.	7,644	42 (33, 68)	36 (30, 47)	<0.001
Max. ALT, U/L	8,722	53 (27, 161)	40 (23, 91)	<0.001

Max. AST, U/L	8,639	86 (43, 308)	54 (32, 128)	<0.001
Max. Total Bilirubin, mg/dL	8,669	0.8 (0.3, 2.3)	0.6 (0.3, 2.1)	<0.001
Min. Albumin, g/dL	10,067	2.4 (2.0, 2.8)	2.6 (2.2, 3.1)	<0.001
Max. BUN, g/dL	14,407	15 (9, 26)	11 (7, 18)	<0.001
Max. Creatinine, g/dL	14,267	0.5 (0.3, 0.9)	0.4 (0.3, 0.6)	<0.001
Max. Glucose, g/dL	14,225	196 (143, 285)	148 (117, 206)	<0.001
Min. pH	12,037	7.21 (7.10, 7.29)	7.30 (7.23, 7.35)	<0.001
Min. Bicarbonate, mEq/L	14,584	19 (15, 22)	21 (18, 23)	<0.001
Max. Lactate, mmol/L	9,294	2.9 (1.6, 6.3)	1.8 (1.1, 3.1)	<0.001
Min. PaO ₂ , mmH	6,726	63 (52, 76)	74 (59, 95)	<0.001
Max. PaCO ₂ , mmHg	6,726	55 (45, 68)	46 (40, 54)	<0.001

636 *minimum (min.) or maximum (max.) value within 72 hours of admission, as indicated

637 Abbreviations: *IQR*, inter-quartile range; *Abs.*, absolute; *WBC*, white blood cell count; *CRP*, c-

638 reactive protein ; *INR*, international normalized ratio; *PTT*, partial thromboplastin time ; *ALT*,

639 alanine aminotransferase; *AST*, aspartate aminotransferase ; *BUN*, blood urea nitrogen; *PaO₂*,

640 partial pressure of arterial oxygen; *PaCO₂*, partial pressure of arterial carbon dioxide.

641


642

643

644

Persistent Hypoxemia and Shock Phenotype

medRxiv preprint doi: <https://doi.org/10.1101/2022.12.23.22283912>; this version posted December 26, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Other Sepsis-associated MODS

